US20080132517A1 - Method of enhancing absorptions of transmucosal administration formulations - Google Patents
Method of enhancing absorptions of transmucosal administration formulations Download PDFInfo
- Publication number
- US20080132517A1 US20080132517A1 US12/017,260 US1726008A US2008132517A1 US 20080132517 A1 US20080132517 A1 US 20080132517A1 US 1726008 A US1726008 A US 1726008A US 2008132517 A1 US2008132517 A1 US 2008132517A1
- Authority
- US
- United States
- Prior art keywords
- medicament
- compound
- propranolol
- sildenafil
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention is directed to a method for enhancing absorption of a medicament that is suitable for transmucosal administration, particularly to a method for enhancing absorption of a medicament suitable for sublingual administration.
- Transmucosal drug delivery system has been studied for years because it can avoid the liver first-pass effect.
- the study on this field focuses on how to enhance absorption of the drug.
- General approaches reported to enhance absorption include the use of various permeation enhancers such as bile salts, surfactants, organic solvents, chelating agents as well as salicylate and Azone®.
- Factors affecting the permeation of a drug via oral mucosa include solubility of the drug, partition coefficient, degree of ionization of the drug, and molecular size and weight of the drug. For a given drug, the molecular size and weight are fixed and cannot be changed. Changes in solubility and degree of ionization will influence partition coefficient and permeability. Therefore, optimization of combined solubility and ionization are variable factors to achieving maximum rate and extent of absorption through oral mucosa such as sublingual mucosa.
- a first aspect of the preferred embodiments provides a method for enhancing absorption of a medicament that is suitable for administering transmucosally, such as sublingually in a subject.
- the medicament used in the preferred embodiments includes a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or a combination thereof and a pharmaceutically acceptable carrier.
- the inventors have found that maximum flux of ionized and non-ionized forms of an active compound of a medicament across the mucosal membrane can be achieved with the attainment of a pH in a mucosal medium by involving certain amount of buffering agents with the medicament,
- the method of the preferred embodiments comprises providing an environment for the administration with a pH of about:
- K a is the ionization constant (dissociation constant) of the active compound in water
- S i is the solubility of the ionized form of the compound
- S u is the solubility of the non-ionized form of the compound.
- a second aspect of the preferred embodiments is to provide a method for enhancing absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally to a subject, comprising providing an environment of the administration with a pH range of about 7.2 to about 7.8.
- a third aspect of the preferred embodiments is to provide a medicament suitable for a transmucosal administration to a subject, comprising an effective amount of propranolol or a pharmaceutically acceptable form thereof and a pharmaceutically acceptable carrier, in which the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- a fourth aspect of the preferred embodiments is to provide a method for treating cardiovascular diseases of a subject comprising transmucosally administering a therapeutically effective amount of propranolol or a pharmaceutically acceptable form thereof to the subject in an environment with a pH range of about 7.2 to about 7.8.
- the formulation of the preferred embodiments can significantly decrease the heart rate in a subject in a very short time, and can be used to treat cardiovascular related diseases (urgent medical conditions) such as atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
- cardiovascular related diseases include atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
- FIG. 1 shows mean heart rates of two healthy subjects after sublingually administering propranolol powder in various pH values
- FIG. 2 shows a change of heart rate after administered with equivalent sublingual dose of a buffered propranolol tablet of the preferred embodiments versus a conventional Inderal tablet in 2 healthy subjects.
- FIG. 3 shows time-plasma concentration profiles (0-420 min) of buffered propranolol tablets of the invention and Inderal (conventional tablet) in 8 male healthy subjects (*p ⁇ 0.05, **p ⁇ 0.01 by paired-samples t-test).
- FIG. 4 shows time-plasma concentration profiles (0-100 min) of buffered propranolol tablets of the invention and Inderal (conventional tablets) in 8 male healthy subjects (*p ⁇ 0.05, **p ⁇ 0.01).
- the preferred embodiments provide a method for enhancing absorption of a medicament that is suitably administrated transmucosally.
- the medicament is administered sublingually by adjusting the pH of the environment of administration of the medicament.
- an active compound of a medicament can be significantly absorbed when an environment of the administration of the medicament is kept around:
- K a is the ionization constant (dissociation constant) of the active compound of the medicament in water
- S i is the solubility of the ionized form of the compound
- S u is the solubility of the non-ionized form of the compound.
- S i and S u can be easily obtained by measuring the drug solubility at two extreme pH levels where the ionized or non-ionized species are dominating. For example, after determining the S i and S u of propranolol and sildenafil, their pH max values are calculated to be 7.62 and 4.25, respectively.
- an ionizable medicament to transport across the mucosa includes both the ionized form and the non-ionized form of the medicament.
- the overall steady-state flux (J ss ) and the apparent permeability coefficient (P app ) of a medicament across the mucosa are the summations of the individual contribution from both the ionized and the non-ionized forms. Therefore, the J ss and P app of such a medicament permeate across the mucosa can be expressed by the following equations:
- J ss J ss ⁇ ( u ) + J ss ⁇ ( i ) ( 3 )
- P app P i ⁇ X i + P u ⁇ X u ( 4 )
- C 0 C i + C u ( 5 )
- J ss(u) and J ss(i) are the steady-state flux of the ionized form and the non-ionized form of the medicament, respectively;
- Q u and Q i are the accumulated amount of the ionized form and the non-ionized form of the medicament penetrated across the mucosa, respectively;
- A is the surface area of the mucosa;
- Co is the loading concentration of the medicament;
- P i and P u are the permeability coefficient of the ionized form and the non-ionized form, respectively;
- X i and X u are the fraction of the ionized form and the non-ionized form, respectively; and
- C i and C u are the concentration of the ionized and non-ionized forms, respectively.
- the term “absorption”, unless specified otherwise, means “penetration” of the active compound of the medicament through the mucosa.
- transmucosal means any route of the administration via the mucosal membrane. Examples include, but are not limited to, sublingual, nasal, vaginal and rectal. In the preferred embodiments, the administration is preferably performed sublingually.
- environment or “environment of an administration” means an environment where an active compound of a medicament is absorbed by permeation across the mucosa.
- the environment is saliva, which contains the drug and is “bathing” the sublingual mucosal membrane.
- subject means animals and human. Human is preferable in the preferred embodiments.
- the method of the preferred embodiments which provides an environment with a certain pH includes providing the environment with a preferable pH during the administration of the medicament, and making a suitable formulation of the medicament in such a way that the medicament itself can provide the environment with a desired pH.
- the latter is preferably.
- buffering agents are preferably involved in the formulation.
- Buffering agents that can be used in the preferred embodiments will be obvious for those skilled in the art. Please see “Handbooks Pharmaceutical Excipients (Second Edition), edited by Ainley Wade and Paul J W Weller, The Pharmaceutical Press London, 1994”, which is incorporated herein by reference.
- Exemplified buffering agents include, but are not limited to, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; citrates, such as sodium citrate (anhydrous or dehydrate); bicarbonates, such as sodium bicarbonate and potassium bicarbonate.
- the amount of buffering agents used in the medicament is readily determined by those skilled in the art, which depend on preferable pH values.
- the medicaments of the preferred embodiments can include various formulations dependent on the dosage forms or formulations of administration.
- the medicament can be in the form of tablets, pills, pellets, powders or sprays.
- suitable formulations include, but are not limited to, ointments, capsules, solutions, syrups, drops, granules and suppositories.
- the medicament can include a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or either entity and a pharmaceutically acceptable carrier.
- Examples of the active compounds include, but are not limited to, propranolol, scopolamine, estradiol, sildenafil, fentanyl, morphine, buprenorphine, butorphanol, methadone, diamorphine, piroxicam, flurbiprofen, indomethacin, naproxen, sulindac, tenoxicam and nifedipine.
- propranolol is preferable.
- the carrier suitably used in the preferred embodiments depends on the specific formulation of the medicament, which is known by those skilled in the art.
- the carriers include, without limitation, fillers, binders, lubricants, diluents, sweetening and flavoring agents, preservatives, disintegrators, grilling agents, permeation enhancers.
- the carriers include starch, gelatin, natural sugars, corn, natural and synthetic gums such as acacia, sodium alginate, methylcellulose, carboxymethylcellulose, polyethylene glycol, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, agar, bentonite, agar gum, stearates such as sodium stearate, HPMC, and palmitic acid, dimethyl sulfoxide, N,N-dimethyl acetamide, N,N-dimethylformamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, N,N-dimethyl-m-toluamide, urea, ethyl acetate, 1-dodecylazacycloheptan-2-one (Azone®), oleic acid, ethylene vinylacetate copo
- Medicaments suitably used in the preferred embodiments are those suitably administered transmucosally which are well known by one skilled in the art.
- Propranolol 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol, a nonselective ⁇ 1 and ⁇ 2 -adrenergic antagonist, has been widely used in the treatment, amelioration, or prophylaxis of diseases associated with cardiovascular system, such as essential arterial hypertension, ischemic heart disease and atrial fibrillation.
- the indication of the propranolol includes management of angina pectoris; long term prophylaxis after recovery from myocardial infarction; control of most forms of cardiac dysrhythmias; control of essential and renal hypertension; prophylaxis of migraine; control of anxiety and anxiety tachycardia; management of essential tremor; adjunctive management of thyrotoxicosis and thyrotoxic crisis; management of hypertrophic obstructive cardiomyopathy; management of phaeochromocytoma (with an alpha-adrenoreceptor blocking medicine), etc.
- injection and oral tablets are the only two dosage forms marketed commercially. Intravenous or intramuscular administration of propranolol can achieve fast onset of action. However, they are inconvenient and not suitable for self-medication.
- the preferred embodiments provide a method for enhancing the absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally in a subject, comprising providing an environment for the administration with a pH range of about 7.2 to about 7.8; and a medicament of propranolol that is suitably administered sublingually to a subject.
- the medicament propranolol of the preferred embodiments comprises an effective amount of propranolol or a pharmaceutically acceptable form thereof and a pharmaceutically acceptable carrier, provided that the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- the medicament contains an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier as described above, which can be formulated as a tablet, pill, pellet, spray, or powder, preferably as a tablet for sublingual administration.
- active compound propranolol can be used in the form of any pharmaceutically acceptable form such as free base, acidic salts, hydrates thereof, and acidic salts of the hydrates.
- the acidic salt form of propranolol is preferable because propranolol is a weak base.
- the acidic salts include, but are not limited to, a salt with inorganic acids such as hydrochloride, sulfate, and phosphate; and a salt with organic acids such as maleate, benzsulfonate acid, and citrate.
- a salt with inorganic acids such as hydrochloride, sulfate, and phosphate
- organic acids such as maleate, benzsulfonate acid, and citrate.
- buffering agents chosen include sodium bicarbonate, sodium phosphate, or a combination of borates and sodium hydroxide.
- buffering agents Na 2 HPO 4 , Na 2 HPO 4 —NaH 2 PO 4 , Na 2 HPO 4 -citric acid, and Tris-HCl Preferable examples include buffering agents Na 2 HPO 4 , Na 2 HPO 4 —NaH 2 PO 4 , Na 2 HPO 4 -citric acid, and Tris-HCl.
- disodium hydrogen phosphate by weight of about 10-25%, was found to effectively control the pH of saliva to be about 7.2 to about 7.8.
- the medicament of propranolol of the preferred embodiments comprises an effective amount of an active component, and a suitable carrier.
- effective amount means about 0.01 to about 99.99% in the formulation by weight.
- the active compound propranolol accounts for about 1-90% in the formulation by weight. More preferably, the active component accounts for about 2-50% in the formulation by weight and most preferably, about 5-10% in the formulation by weight.
- the amount of the active component mentioned in the preferred embodiments means the amount of free compound of propranolol.
- the formulation of the preferred embodiments can be prepared to contain an amount of propranolol as those commercially available such as about 10 mg, 20 mg, 40 mg, or 80 mg in a tablet. It is also suitable that the formation may contain propranolol in an amount less than that commercially available, when it is used for urgent situations. Those skilled in the art will readily determine a suitable amount of propranolol in a specific formulation suitable for a given patient.
- Propranolol powder was mixed with magnesium stearate. To the resulting mixture was added other components, and then commingled in a V-blender for 15 minutes. The thoroughly blended composition was compressed into 1,000 plain tablets, each with 5 mm in diameter and 2-3 mm in thickness.
- the subjects were placed in a seated position for about 30 min prior to baseline measurements being made.
- a Dinamap BP monitor Wipro GE Co., USA
- each subject was refrained from swallowing any propranolol or saliva until about 25 minutes, then the saliva was spit out and collected for pH measurement. Subsequently the mouth was rinsed 4 times with pure water.
- Pharmacodynamic parameters such as heart rate and blood pressure were measured. The heart rate change is shown in FIG. 1 The blood pressure changes were variable and no significant hypotension occurred.
- the reduction of heart rate was highly dependent on the pH of saliva achieved from various buffering agents in the formulations ( FIG. 1 ).
- Subjects receiving formulation 3 showed a drop of more than 10% of heart rate following 10 minutes of administration of sublingual propranolol, which is much faster onset of action than other formulations with different saliva pHs.
- Propranolol hydrochloride was ordered from Chang Zhou Guangming Biochemical Laboratories (BP 2000/USP24). Sodium dihydrogen phosphate and HPMC (50 cps) were supplied by Sigma-Aldrich Co. (St. Louis, Mo., USA). Lactose monohydrate was supplied by Fisher Scientific UK Ltd. (Leicestershire, UK). Magnesium stearate was obtained form Wing Hing (Hong Kong).
- the saliva pH of the Inderal tablet and that of the buffered tablet of the preferred embodiments were shown in Table 2. These results were shown in FIG. 2 .
- the results showed that the buffered formulation quickly reduced 8% heart rate after 10 min of sublingual administration.
- the effect of the Inderal tablet was delayed to over 15 minutes and only a 6% reduction of heart rate.
- the heart rate continued to decrease with both the formulations, reaching a maximum effect around 20 minutes,
- the mean maximum effect of the buffered propranolol tablet was about 12% reduction whereas the Inderal tablet only about 7% reduction.
- the effect on the blood pressure was variable following both the formulations and no significant hypotension was observed.
- the doses of propranolol in the buffered tablets and conventional tablets employed in the trail are identical at 40 mg. After 15 minutes sublingually, each subject swallowed the dissolved propranolol and followed by swallowing additional 1 cup of water.
- Venous blood samples (5 ml) were collected via a cannula inserted in the antecubital vein at 0, 3, 6, 10, 15, 30, 45, 60, 90, 150, 300, and 420 minutes after drug administration.
- Drug concentrations in plasma were determined by HPLC. Propranolol plasma concentration versus time profiles was then analyzed using a non-compartmental model. The time-plasma concentration profiles of the two formulations were plotted as shown in FIG. 3 and FIG. 4 .
- T max Time of occurrence for the maximum (peak) drug concentration
- V z /F Volume of distribution based on the terminal phase
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/220,491 (allowed), filed Sep. 7, 2005, which is a continuation-in-part of U.S. patent application Ser. No. 10/935,899, filed on Sep. 8, 2004 (abandoned). The content of these applications is incorporated herein by reference in their entirety.
- 1. Field of the Invention
- The present invention is directed to a method for enhancing absorption of a medicament that is suitable for transmucosal administration, particularly to a method for enhancing absorption of a medicament suitable for sublingual administration.
- 2. Description of the Related Art
- Transmucosal drug delivery system has been studied for years because it can avoid the liver first-pass effect. The study on this field focuses on how to enhance absorption of the drug. General approaches reported to enhance absorption include the use of various permeation enhancers such as bile salts, surfactants, organic solvents, chelating agents as well as salicylate and Azone®.
- Factors affecting the permeation of a drug via oral mucosa, such as sublingual mucosa, include solubility of the drug, partition coefficient, degree of ionization of the drug, and molecular size and weight of the drug. For a given drug, the molecular size and weight are fixed and cannot be changed. Changes in solubility and degree of ionization will influence partition coefficient and permeability. Therefore, optimization of combined solubility and ionization are variable factors to achieving maximum rate and extent of absorption through oral mucosa such as sublingual mucosa.
- A first aspect of the preferred embodiments provides a method for enhancing absorption of a medicament that is suitable for administering transmucosally, such as sublingually in a subject. The medicament used in the preferred embodiments includes a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or a combination thereof and a pharmaceutically acceptable carrier.
- The inventors have found that maximum flux of ionized and non-ionized forms of an active compound of a medicament across the mucosal membrane can be achieved with the attainment of a pH in a mucosal medium by involving certain amount of buffering agents with the medicament, The method of the preferred embodiments comprises providing an environment for the administration with a pH of about:
-
- in which Ka is the ionization constant (dissociation constant) of the active compound in water, Si is the solubility of the ionized form of the compound, and Su is the solubility of the non-ionized form of the compound.
- A second aspect of the preferred embodiments is to provide a method for enhancing absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally to a subject, comprising providing an environment of the administration with a pH range of about 7.2 to about 7.8.
- A third aspect of the preferred embodiments is to provide a medicament suitable for a transmucosal administration to a subject, comprising an effective amount of propranolol or a pharmaceutically acceptable form thereof and a pharmaceutically acceptable carrier, in which the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- A fourth aspect of the preferred embodiments is to provide a method for treating cardiovascular diseases of a subject comprising transmucosally administering a therapeutically effective amount of propranolol or a pharmaceutically acceptable form thereof to the subject in an environment with a pH range of about 7.2 to about 7.8.
- Compared to a conventional formulation of propranolol, the formulation of the preferred embodiments can significantly decrease the heart rate in a subject in a very short time, and can be used to treat cardiovascular related diseases (urgent medical conditions) such as atrial fibrillation with rapid heart rate, panic attacks with rapid heart rate, acute hypertension, headache and angina.
-
FIG. 1 shows mean heart rates of two healthy subjects after sublingually administering propranolol powder in various pH values; and -
FIG. 2 shows a change of heart rate after administered with equivalent sublingual dose of a buffered propranolol tablet of the preferred embodiments versus a conventional Inderal tablet in 2 healthy subjects. -
FIG. 3 shows time-plasma concentration profiles (0-420 min) of buffered propranolol tablets of the invention and Inderal (conventional tablet) in 8 male healthy subjects (*p<0.05, **p<0.01 by paired-samples t-test). -
FIG. 4 shows time-plasma concentration profiles (0-100 min) of buffered propranolol tablets of the invention and Inderal (conventional tablets) in 8 male healthy subjects (*p<0.05, **p<0.01). - As stated above, the preferred embodiments provide a method for enhancing absorption of a medicament that is suitably administrated transmucosally. In one embodiment, the medicament is administered sublingually by adjusting the pH of the environment of administration of the medicament. We found that an active compound of a medicament can be significantly absorbed when an environment of the administration of the medicament is kept around:
-
- in which Ka is the ionization constant (dissociation constant) of the active compound of the medicament in water, Si is the solubility of the ionized form of the compound, and Su is the solubility of the non-ionized form of the compound. Si and Su can be easily obtained by measuring the drug solubility at two extreme pH levels where the ionized or non-ionized species are dominating. For example, after determining the Si and Su of propranolol and sildenafil, their pHmax values are calculated to be 7.62 and 4.25, respectively.
- Theoretically, an ionizable medicament to transport across the mucosa includes both the ionized form and the non-ionized form of the medicament. The overall steady-state flux (Jss) and the apparent permeability coefficient (Papp) of a medicament across the mucosa are the summations of the individual contribution from both the ionized and the non-ionized forms. Therefore, the Jss and Papp of such a medicament permeate across the mucosa can be expressed by the following equations:
-
- In the above equations, Jss(u) and Jss(i) are the steady-state flux of the ionized form and the non-ionized form of the medicament, respectively; Qu and Qi are the accumulated amount of the ionized form and the non-ionized form of the medicament penetrated across the mucosa, respectively; A is the surface area of the mucosa; Co is the loading concentration of the medicament; Pi and Pu are the permeability coefficient of the ionized form and the non-ionized form, respectively; Xi and Xu are the fraction of the ionized form and the non-ionized form, respectively; and Ci and Cu are the concentration of the ionized and non-ionized forms, respectively. Unlike Jss(u) and Jss(i), Pi and Pu are all independent of pH of the solution (environment). Therefore, we would expect that maximal Ci and Cu will be reached at an optimal pHmax, which will be the solubility of the ionized form (Si) and the non-ionized form (Su), respectively, and the maximal steady-state flux can be obtained accordingly.
-
- It is expected that the best flux of the medicament across the mucosa would be achieved if we could achieve the pHmax in the environment with a certain amount of buffering agents in a specific formulation of the medicament.
- As used herein, the term “absorption”, unless specified otherwise, means “penetration” of the active compound of the medicament through the mucosa.
- The term “transmucosal”, unless specified otherwise, means any route of the administration via the mucosal membrane. Examples include, but are not limited to, sublingual, nasal, vaginal and rectal. In the preferred embodiments, the administration is preferably performed sublingually.
- The term “environment” or “environment of an administration” means an environment where an active compound of a medicament is absorbed by permeation across the mucosa. For example, when the administration is performed sublingually, the environment is saliva, which contains the drug and is “bathing” the sublingual mucosal membrane.
- The term “subject” means animals and human. Human is preferable in the preferred embodiments.
- The method of the preferred embodiments which provides an environment with a certain pH includes providing the environment with a preferable pH during the administration of the medicament, and making a suitable formulation of the medicament in such a way that the medicament itself can provide the environment with a desired pH. In the preferred embodiments, the latter is preferably. In this case, buffering agents are preferably involved in the formulation.
- Buffering agents that can be used in the preferred embodiments will be obvious for those skilled in the art. Please see “Handbooks Pharmaceutical Excipients (Second Edition), edited by Ainley Wade and Paul J W Weller, The Pharmaceutical Press London, 1994”, which is incorporated herein by reference. Exemplified buffering agents include, but are not limited to, phosphates, such as sodium phosphate; phosphates monobasic, such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; phosphates dibasic, such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; citrates, such as sodium citrate (anhydrous or dehydrate); bicarbonates, such as sodium bicarbonate and potassium bicarbonate. The amount of buffering agents used in the medicament is readily determined by those skilled in the art, which depend on preferable pH values.
- The medicaments of the preferred embodiments can include various formulations dependent on the dosage forms or formulations of administration. For example, if the medicament is administered sublingually, it can be in the form of tablets, pills, pellets, powders or sprays. Examples of other suitable formulations include, but are not limited to, ointments, capsules, solutions, syrups, drops, granules and suppositories. In any formulation, the medicament can include a therapeutically effective amount of an active compound or a pharmaceutically acceptable form thereof or either entity and a pharmaceutically acceptable carrier. Examples of the active compounds include, but are not limited to, propranolol, scopolamine, estradiol, sildenafil, fentanyl, morphine, buprenorphine, butorphanol, methadone, diamorphine, piroxicam, flurbiprofen, indomethacin, naproxen, sulindac, tenoxicam and nifedipine. In the preferred embodiments, propranolol is preferable.
- The carrier suitably used in the preferred embodiments depends on the specific formulation of the medicament, which is known by those skilled in the art. The carriers include, without limitation, fillers, binders, lubricants, diluents, sweetening and flavoring agents, preservatives, disintegrators, grilling agents, permeation enhancers. Examples of the carriers include starch, gelatin, natural sugars, corn, natural and synthetic gums such as acacia, sodium alginate, methylcellulose, carboxymethylcellulose, polyethylene glycol, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, agar, bentonite, agar gum, stearates such as sodium stearate, HPMC, and palmitic acid, dimethyl sulfoxide, N,N-dimethyl acetamide, N,N-dimethylformamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid, N,N-dimethyl-m-toluamide, urea, ethyl acetate, 1-dodecylazacycloheptan-2-one (Azone®), oleic acid, ethylene vinylacetate copolymer, polyvincyl chloride, polyethylene, polydiethyl phthalate.
- Medicaments suitably used in the preferred embodiments are those suitably administered transmucosally which are well known by one skilled in the art.
- Propranolol, 1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol, a nonselective β1 and β2-adrenergic antagonist, has been widely used in the treatment, amelioration, or prophylaxis of diseases associated with cardiovascular system, such as essential arterial hypertension, ischemic heart disease and atrial fibrillation. The indication of the propranolol, for example, includes management of angina pectoris; long term prophylaxis after recovery from myocardial infarction; control of most forms of cardiac dysrhythmias; control of essential and renal hypertension; prophylaxis of migraine; control of anxiety and anxiety tachycardia; management of essential tremor; adjunctive management of thyrotoxicosis and thyrotoxic crisis; management of hypertrophic obstructive cardiomyopathy; management of phaeochromocytoma (with an alpha-adrenoreceptor blocking medicine), etc. At present, injection and oral tablets are the only two dosage forms marketed commercially. Intravenous or intramuscular administration of propranolol can achieve fast onset of action. However, they are inconvenient and not suitable for self-medication.
- Though oral administration of propranolol tablets has proven to be safe and effective in the treatment of atrial fibrillation, its onset of action is usually over 1 hr. Also, due to extensive hepatic first-pass effect, it has a short plasma half-life (2.8-4.4 hr), and a low bioavailability (10-30%).
- To overcome these drawbacks, the preferred embodiments provide a method for enhancing the absorption of a medicament comprising propranolol or a pharmaceutically acceptable form thereof that is administered transmucosally in a subject, comprising providing an environment for the administration with a pH range of about 7.2 to about 7.8; and a medicament of propranolol that is suitably administered sublingually to a subject. The medicament propranolol of the preferred embodiments comprises an effective amount of propranolol or a pharmaceutically acceptable form thereof and a pharmaceutically acceptable carrier, provided that the medicament provides an environment of the administration with a pH range of about 7.2 to about 7.8.
- In the preferred embodiments, the medicament contains an effective amount of propranolol or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier as described above, which can be formulated as a tablet, pill, pellet, spray, or powder, preferably as a tablet for sublingual administration. In the formulation, active compound propranolol can be used in the form of any pharmaceutically acceptable form such as free base, acidic salts, hydrates thereof, and acidic salts of the hydrates. In the pre ferred embodiments, the acidic salt form of propranolol is preferable because propranolol is a weak base. The acidic salts include, but are not limited to, a salt with inorganic acids such as hydrochloride, sulfate, and phosphate; and a salt with organic acids such as maleate, benzsulfonate acid, and citrate. It should be understood that the dose forms suitable for sublingual administration will have the same indications as those for the conventional dose forms, such as disclosed on www.medsafe.govt.nz/profs.htm for Apo-Propranoal™ and Angilol™, which is hereby incorporated herein by reference in its entirety.
- It has been investigated that permeability across the sublingual mucosa is dependent on the concentration of non-ionized propranolol in the environment. When a formulation of propranolol provides saliva with pH of about 7.2 to about 7.8, propranolol should maintain relatively high solubility as well as high fraction of non-ionized form in the saliva of human oral cavity. Preferably, the formulation for sublingual delivery is at about pH 7.6. This can be confirmed by equation (I). For propranolol. Si is 22.118 (mg/ml), Su is 0.539 (mg/ml) and Ka is 10 −9.23.
-
- To achieve this, buffering agents chosen include sodium bicarbonate, sodium phosphate, or a combination of borates and sodium hydroxide. Preferable examples include buffering agents Na2HPO4, Na2HPO4—NaH2PO4, Na2HPO4-citric acid, and Tris-HCl. Specifically, disodium hydrogen phosphate, by weight of about 10-25%, was found to effectively control the pH of saliva to be about 7.2 to about 7.8.
- The medicament of propranolol of the preferred embodiments comprises an effective amount of an active component, and a suitable carrier. The term of “effective amount” means about 0.01 to about 99.99% in the formulation by weight. Preferably, the active compound propranolol accounts for about 1-90% in the formulation by weight. More preferably, the active component accounts for about 2-50% in the formulation by weight and most preferably, about 5-10% in the formulation by weight.
- The amount of the active component mentioned in the preferred embodiments, unless specified otherwise, means the amount of free compound of propranolol. The formulation of the preferred embodiments can be prepared to contain an amount of propranolol as those commercially available such as about 10 mg, 20 mg, 40 mg, or 80 mg in a tablet. It is also suitable that the formation may contain propranolol in an amount less than that commercially available, when it is used for urgent situations. Those skilled in the art will readily determine a suitable amount of propranolol in a specific formulation suitable for a given patient.
-
-
Ingredients Weight (g) Propranolol hydrochloride 40 Disodium hydrogen phosphate 40 Lactose monohydrate 109 HPMC 20 Magnesium stearate 2 - Propranolol powder was mixed with magnesium stearate. To the resulting mixture was added other components, and then commingled in a V-blender for 15 minutes. The thoroughly blended composition was compressed into 1,000 plain tablets, each with 5 mm in diameter and 2-3 mm in thickness.
-
-
Ingredients Weight (g) Propranolol hydrochloride 20 Sodium dihydrogen phosphate 40 Lactose 129 HPMC 20 Magnesium stearate 2 - All ingredients were formed as 1,000 tablets in the same way as in Example 1.
-
-
Ingredients Weight (g) Propranolol hydrochloride 20 Sodium dihydrogen phosphate 1.5 Disodium hydrogen phosphate 38.5 Lactose monohydrate 109 HPMC 20 Magnesium stearate 2 - All ingredients were formed as 1,000 tablets in the same way as in Example 1.
- Two healthy male subjects took part in the preliminary pharmacodynamic investigation of sublingual administration of buffered propranolol powder with 4 different buffering capacities as shown in Table 1.
-
TABLE 1 Pro- pran- Saliva Formu- Dosage olol pH Disappeared lations Forms (mg) Buffering Agent (Mean) (% Mean) 1 Powder 20 0 7.13 45.64 2 Powder 20 38.2 mg Na2HPO4 and 7.37 48.34 1.8 mg NaH2PO4 3 Powder 20 40 mg Na2HPO4 7.64 55.56 4 Powder 20 20 mg NaHCO3 7.88 44.35 - The subjects had not taken any sublingual medicine 2 weeks prior to and during the period of the study. Alcohol and smoking were not permitted for 24 hr prior to, and for the duration of the study. Caffeine-containing products were also not allowed from 8 hr prior to, and during, each study period.
- The subjects were placed in a seated position for about 30 min prior to baseline measurements being made. A Dinamap BP monitor (Wipro GE Co., USA) was used to record systolic, diastolic, and mean blood pressure and heart rate every minute for 10 minutes before administration of sublingual propranolol tablet. After sublingual administration, each subject was refrained from swallowing any propranolol or saliva until about 25 minutes, then the saliva was spit out and collected for pH measurement. Subsequently the mouth was rinsed 4 times with pure water. Pharmacodynamic parameters such as heart rate and blood pressure were measured. The heart rate change is shown in
FIG. 1 The blood pressure changes were variable and no significant hypotension occurred. - The reduction of heart rate was highly dependent on the pH of saliva achieved from various buffering agents in the formulations (
FIG. 1 ).Subjects receiving formulation 3 showed a drop of more than 10% of heart rate following 10 minutes of administration of sublingual propranolol, which is much faster onset of action than other formulations with different saliva pHs. - Moreover, the maximal reduction of heart rate was 17% for
formulation 3, whereas only 5-10% maximal reductions were found for the other formulations. These results indicated thatformulation 3 could effectively enhance the sublingual absorption of propranolol and rapidly reduce the heart rate in comparison to other 3 formulations. - Propranolol hydrochloride was ordered from Chang Zhou Guangming Biochemical Laboratories (BP 2000/USP24). Sodium dihydrogen phosphate and HPMC (50 cps) were supplied by Sigma-Aldrich Co. (St. Louis, Mo., USA). Lactose monohydrate was supplied by Fisher Scientific UK Ltd. (Leicestershire, UK). Magnesium stearate was obtained form Wing Hing (Hong Kong).
-
Inderal 40 mg propranolol tablets were purchased from AstraZeneca UK Ltd. (Macclesfield Cheshire, UK). - Two healthy male subjects took part in the preliminary pharmacodynamic investigation once with buffered sublingual propranolol tablets as prepared in Example 1 and the Inderal tablet in the same dose of 40 mg propranolol, respectively. The procedure of this study was similar to that described in
Experiment 1 except that following the tablet, and the saliva was spit out in 8 minutes. - The saliva pH of the Inderal tablet and that of the buffered tablet of the preferred embodiments were shown in Table 2. These results were shown in
FIG. 2 . The results showed that the buffered formulation quickly reduced 8% heart rate after 10 min of sublingual administration. However, the effect of the Inderal tablet was delayed to over 15 minutes and only a 6% reduction of heart rate. The heart rate continued to decrease with both the formulations, reaching a maximum effect around 20 minutes, The mean maximum effect of the buffered propranolol tablet was about 12% reduction whereas the Inderal tablet only about 7% reduction. The effect on the blood pressure was variable following both the formulations and no significant hypotension was observed. -
TABLE 2 Saliva pH Dosage forms (Mean ± SD) (n = 2) Inderal tablet 6.82 ± 0.10 Buffered tablet 7.52 ± 0.05 - The study was conducted using a single dose, two-treatment, cross-over design. Eight healthy male subjects were randomly assigned to two groups, one with 4 of the subjects receiving a single dose of buffered tablets sublingually, and the other with the rest of the subjects receiving a single dose of conventional tablets (Inderal) sublingually. The doses of propranolol in the buffered tablets and conventional tablets employed in the trail are identical at 40 mg. After 15 minutes sublingually, each subject swallowed the dissolved propranolol and followed by swallowing additional 1 cup of water. After a washout period of 2 weeks, each subject was crossed over to receive the other formulation, Venous blood samples (5 ml) were collected via a cannula inserted in the antecubital vein at 0, 3, 6, 10, 15, 30, 45, 60, 90, 150, 300, and 420 minutes after drug administration. Drug concentrations in plasma were determined by HPLC. Propranolol plasma concentration versus time profiles was then analyzed using a non-compartmental model. The time-plasma concentration profiles of the two formulations were plotted as shown in
FIG. 3 andFIG. 4 . - Pharmacokinetic parameters of buffered propranolol tablet and Inderal (conventional tablet) after sublingual administration in eight male healthy subjects (By Paired-Samples T-test) in the above study were calculated using non-compartment model and summarized in Table 3.
-
TABLE 3 Buffered Tablets Inderal Tablets Parameters (Mean ± SD) (Mean ± SD) p-Values Teff (min) 8.5 ± 7.7 38.8 ± 20.4 0.004 Tmax (min) 78.8 ± 50.6 99.4 ± 44.6 0.173 Cmax (ng/ml) 58.3 ± 21.3 51.7 ± 11.8 0.287 λz (min−1) 0.0036 ± 0.0011 0.0036 ± 0.0010 0.826 t1/2 (min) 203 ± 48 210 ± 68 0.074 AUC0-15 min 310.6 ± 177.8 79.3 ± 68.8 0.019 (ng · min/ml) AUC0-30 min 908.8 ± 450.4 306.9 ± 209.0 0.015 (ng · min/ml) AUC0-420 min 16582 ± 6634 13305 ± 4683 0.067 (ng · min/ml) AUC∞ (ng · min/ml) 22973 ± 10096 19864 ± 10142 0.269 Vz/F (L) 608.3 ± 287.5 694.4 ± 242.1 0.275 CL/F (ml/min) 2312.7 ± 1765.8 2569.8 ± 1399 0.622 MRT0-420 min (min) 179.6 ± 18.0 187.3 ± 24.4 0.173 - In Table 3, the abbreviations have the following meanings:
- λz—First order rate constant associated with the terminal (log-linear) portion of the curve;
t1/2—Half-life of the drugs; - Our buffered propranolol tablets resulted in a significantly higher and faster onset of plasma concentration than the conventional tablet when administered in the same manner. There was no significance difference in the total systemic exposure (AUC∝)
- Many modifications and variations of the embodiments described herein may be made without departing from the scope, as is apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only.
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/017,260 US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/935,899 US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US11/220,491 US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
US12/017,260 US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/220,491 Continuation US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080132517A1 true US20080132517A1 (en) | 2008-06-05 |
US8012503B2 US8012503B2 (en) | 2011-09-06 |
Family
ID=35996531
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,899 Abandoned US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US11/220,491 Active US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
US12/017,260 Active US8012503B2 (en) | 2004-09-08 | 2008-01-21 | Method of enhancing absorptions of transmucosal administration formulations |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/935,899 Abandoned US20060051413A1 (en) | 2004-09-08 | 2004-09-08 | Method of enhancing absorptions of transmucosal administration formulations |
US11/220,491 Active US7329416B2 (en) | 2004-09-08 | 2005-09-07 | Method of enhancing absorptions of transmucosal administration formulations |
Country Status (8)
Country | Link |
---|---|
US (3) | US20060051413A1 (en) |
EP (1) | EP1786467A4 (en) |
JP (1) | JP2008512363A (en) |
CN (1) | CN100594936C (en) |
AU (1) | AU2005282135B2 (en) |
CA (1) | CA2577740C (en) |
HK (1) | HK1107271A1 (en) |
WO (1) | WO2006026922A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276501A1 (en) * | 2005-05-25 | 2006-12-07 | Transoral Pharmaceuticals, Inc. | Solid compositions for treating middle-of-the-night insomnia |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20080008753A1 (en) * | 2004-02-17 | 2008-01-10 | Singh Nikhilesh N | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20080132535A1 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized Zolpidem Pharmaceutical Compositions |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7804995B2 (en) | 2002-07-02 | 2010-09-28 | Reald Inc. | Stereoscopic format converter |
WO2006093786A2 (en) * | 2005-02-25 | 2006-09-08 | University Of Kentucky Research Foundation | Scopolamine sublingual spray |
PL2054031T3 (en) | 2006-07-21 | 2016-09-30 | Transmucosal delivery devices with enhanced uptake | |
WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
EP3581169A1 (en) * | 2008-01-22 | 2019-12-18 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
WO2009146104A1 (en) | 2008-04-02 | 2009-12-03 | Accentia Biopharmaceuticals, Inc. | Formulations, devices and methods for treating and preventing mucositis |
SG173058A1 (en) * | 2009-01-23 | 2011-08-29 | Hoffmann La Roche | Pharmaceutical composition comprising aleglitazar |
RS53995B1 (en) | 2011-09-19 | 2015-10-30 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
US9248597B2 (en) * | 2012-04-02 | 2016-02-02 | Progressive Components International Corporation | Bubbler base |
EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
CN106714790A (en) | 2014-07-22 | 2017-05-24 | 托马斯·P·杜利 | Pharmaceutical compositions and method for the treatment of symptoms of panic and anxiety using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations |
US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
EP4157449A1 (en) * | 2020-05-26 | 2023-04-05 | Strategic Drug Solutions, Inc. | Formulations and methods for treating erectile dysfunction |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
US6197334B1 (en) * | 1998-04-13 | 2001-03-06 | Donald V. Renda | Lozenge and method of making |
US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522804A (en) * | 1983-01-03 | 1985-06-11 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of propranolol |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
US5785989A (en) * | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US5132114A (en) * | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
DE68922225T2 (en) * | 1985-05-01 | 1995-08-10 | Anesta Corp | COMPRESSED POWDER MEDICAL. |
GB8522453D0 (en) * | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
AU645966B2 (en) * | 1989-09-05 | 1994-02-03 | University Of Utah Research Foundation | Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs |
CN1163263C (en) * | 2000-01-07 | 2004-08-25 | 华中理工大学 | Polypeptide medicine as oral spray |
WO2001089476A1 (en) * | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
CN1335182A (en) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | Insulin spray for oral cavity and its prepn process |
US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
-
2004
- 2004-09-08 US US10/935,899 patent/US20060051413A1/en not_active Abandoned
-
2005
- 2005-09-07 US US11/220,491 patent/US7329416B2/en active Active
- 2005-09-08 EP EP05783988A patent/EP1786467A4/en not_active Withdrawn
- 2005-09-08 JP JP2007529313A patent/JP2008512363A/en active Pending
- 2005-09-08 CA CA2577740A patent/CA2577740C/en not_active Expired - Fee Related
- 2005-09-08 CN CN200580030149A patent/CN100594936C/en not_active Expired - Fee Related
- 2005-09-08 WO PCT/CN2005/001425 patent/WO2006026922A1/en active Application Filing
- 2005-09-08 AU AU2005282135A patent/AU2005282135B2/en not_active Ceased
-
2008
- 2008-01-21 US US12/017,260 patent/US8012503B2/en active Active
- 2008-01-25 HK HK08101014.2A patent/HK1107271A1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855908A (en) * | 1984-05-01 | 1999-01-05 | University Of Utah Research Foundation | Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient |
US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
US6197334B1 (en) * | 1998-04-13 | 2001-03-06 | Donald V. Renda | Lozenge and method of making |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080008753A1 (en) * | 2004-02-17 | 2008-01-10 | Singh Nikhilesh N | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20100291004A1 (en) * | 2004-02-17 | 2010-11-18 | Singh Nikhilesh N | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US7682628B2 (en) | 2004-02-17 | 2010-03-23 | Transcept Pharmaceuticals, Inc. | Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
US20080057119A1 (en) * | 2005-05-25 | 2008-03-06 | Singh Nikhilesh N | Compositions and methods for treating middle-of-the night insomnia |
US20070287740A1 (en) * | 2005-05-25 | 2007-12-13 | Transcept Pharmaceuticals, Inc. | Compositions and methods of treating middle-of-the night insomnia |
US20070225322A1 (en) * | 2005-05-25 | 2007-09-27 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the night insomnia |
US20060276501A1 (en) * | 2005-05-25 | 2006-12-07 | Transoral Pharmaceuticals, Inc. | Solid compositions for treating middle-of-the-night insomnia |
US20070123562A1 (en) * | 2005-05-25 | 2007-05-31 | Transoral Pharmaceuticals, Inc. | Compositions and methods for treating middle-of-the-night insomnia |
US20100249177A1 (en) * | 2005-05-25 | 2010-09-30 | Singh Nikhilesh N | Compositions and methods for treating middle-of-the-night insomnia |
US20100249178A1 (en) * | 2005-05-25 | 2010-09-30 | Nikhilesh Singh | Compositions and methods for treating middle-of-the-night insomnia |
US20070066643A1 (en) * | 2005-05-25 | 2007-03-22 | Transoral Pharmaceuticals, Inc. | Methods of treating middle-of-the-night insomnia |
US20110039881A1 (en) * | 2005-05-25 | 2011-02-17 | Singh Nikhilesh N | Compositions and methods for treating middle-of-the-night insomnia |
US8242131B2 (en) | 2005-05-25 | 2012-08-14 | Transcept Pharmaceuticals, Inc. | Methods of treating middle-of-the-night insomnia |
US8252809B2 (en) | 2005-05-25 | 2012-08-28 | Transcept Pharmaceuticals, Inc. | Compositions for treating insomnia |
US20080132535A1 (en) * | 2006-11-30 | 2008-06-05 | Transcept Pharmaceuticals, Inc. | Stabilized Zolpidem Pharmaceutical Compositions |
Also Published As
Publication number | Publication date |
---|---|
AU2005282135A1 (en) | 2006-03-16 |
HK1107271A1 (en) | 2008-04-03 |
CA2577740A1 (en) | 2006-03-16 |
CN100594936C (en) | 2010-03-24 |
CN101068571A (en) | 2007-11-07 |
US7329416B2 (en) | 2008-02-12 |
US8012503B2 (en) | 2011-09-06 |
EP1786467A1 (en) | 2007-05-23 |
US20060051413A1 (en) | 2006-03-09 |
JP2008512363A (en) | 2008-04-24 |
CA2577740C (en) | 2011-03-15 |
EP1786467A4 (en) | 2010-09-01 |
AU2005282135B2 (en) | 2009-01-22 |
US20060051415A1 (en) | 2006-03-09 |
WO2006026922A1 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8012503B2 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
JP5469868B2 (en) | Degradable oral film | |
JP4172820B2 (en) | Fast-dissolving galantamine hydrobromide tablets | |
ES2538460T3 (en) | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence | |
US20080131508A1 (en) | Oral transmucosal nicotine dosage form | |
US20060062812A1 (en) | Novel compositions | |
RU2010123027A (en) | PHARMACEUTICAL COMPOSITIONS OF DUAL ACTION ON THE BASIS OF NADMOLECULAR STRUCTURES OF ANTAGONISTS / ANGIOTENZINE (ARB) RECEPTOR BLOCK AND NEUTRAL ENDEPEPTIDASE (NEP) INHIBITOR (NEP) | |
JP2012515154A (en) | Formulation for oral mucosal administration of analgesic molecule and / or antispasmodic molecule | |
JP2013515782A (en) | Orally administrable film formulation containing ondansetron | |
US20130095174A1 (en) | Compositions and Methods for Transmucosal Delivery of Lofexidine | |
CA3033897A1 (en) | Liquid naloxone spray | |
US20090214442A1 (en) | Oral Transmucosal Nicotine Dosage Form | |
KR102239291B1 (en) | Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof | |
US20100010029A1 (en) | Acute Pain Medications Based on Fast Acting Diclofenac-Opioid Combinations | |
JP2005523256A (en) | Perindopril oral dispersible pharmaceutical composition | |
US20140235656A1 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
JP5811404B2 (en) | Formulation for buccal transmucosal administration of setron | |
JP2023506537A (en) | Transmucosal therapeutic system containing agomelatine | |
WO2003075919A1 (en) | Tablet containing pilsicainide hydrochloride (dry) | |
MX2010009917A (en) | Modified release composition comprising doxofylline. | |
WO2014191414A1 (en) | Syrup formulation of salbutamol | |
US20110195996A1 (en) | Transmucosal Treatment Methods in Patients With Mucositis | |
JP2006522790A (en) | Pharmaceutical combination comprising eletriptan and sodium bicarbonate | |
JP2022501407A (en) | Oral mucosal solution of zolpidem or its pharmaceutically acceptable salt | |
Dugger III et al. | Immediate-Immediate Release (I2R) Lingual or Buccal Spray Formulations for Transmucosal Delivery of Drug Substances |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |